Analytical Data
-
Gene name
Pret-110
- Application
-
Alternative Names
Protein p12
-
Species
African swine fever virus
-
Source
E. coli
-
Tag
N- His
-
Purity
Greater than 90% as determined by SDS-PAGE.
-
Uniprot
P0C9Y3
-
Expression Region
1-61aa
-
Molecular Weight
12.7 kDa
-
Endotoxin
< 1.0 EU per μg protein as determined by the LAL method.
-
Form
Freeze-dried powder
-
Buffer formulation
PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300.
-
Reconstitution
Reconstitute in ddH2O to a concentration of 0.1-0.5 mg/mL. Do not vortex.
- Customization
-
Stability Test
The thermal stability is described by the loss rate. The loss rate was determined by accelerated thermal degradation test, that is, incubate the protein at 37℃ for 48h, and no obvious degradation and precipitation were observed. The loss rate isless than 8% within the expiration date under appropriate storage condition.
-
Storage & Shelf Life
Samples are stable for up to twelve months from date of receipt at -20℃ to -80℃. Store it under sterile conditions at -20℃ to -80℃. It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
-
Shipping
In general, recombinant proteins are supplied as lyophilized powder and shipped at ambient temperature. For bulk packages, the proteins are provided as frozen liquid and shipped with blue ice, unless otherwise requested by the customer.
Quality inspection process
Related Products
Protein Description
Pret-110 is a recombinant protein that has garnered attention due to its potential applications in various biotechnological fields, particularly in the study of protein interactions and therapeutic developments. The background of Pret-110 research stems from the growing need for proteins that can serve as reliable tools in the analysis of cellular processes, mechanisms of disease, and the development of drug candidates. This protein is often engineered to enhance specific properties, such as stability, solubility, or binding affinity, which are crucial for experimental processes. The advances in recombinant DNA technology allow for the synthesis of Pret-110 in host organisms, making it more accessible for research purposes. Additionally, Pret-110’s unique structural attributes may enable it to act as a biomarker or therapeutic agent in disease models, particularly in cancer and neurodegenerative conditions. Ongoing studies focus on elucidating its interaction pathways, optimizing production methods, and assessing its efficacy in preclinical models, positioning Pret-110 as a promising candidate in drug discovery and basic research. The comprehensive investigation of Pret-110 not only enhances our understanding of protein functionality but also contributes to the broader field of molecular biology and therapeutic innovation.
